Interactive HFA-ICOS Score Calculator
This calculator provides an educational HFA-ICOS-style risk estimate for potential cancer therapy-related cardiovascular toxicity. It is designed for learning and planning conversations, not for diagnosis.
Medical disclaimer: This tool is not an official guideline implementation and should not replace clinical judgment, echocardiography, biomarker testing, or a cardio-oncology consult.
What is the HFA-ICOS score?
The HFA-ICOS framework is used in cardio-oncology to estimate a patient’s baseline risk of developing cardiovascular complications from cancer treatment. In practical terms, it helps clinicians identify who may need closer monitoring before, during, and after therapies that can stress the heart.
The score combines patient characteristics (such as age and existing health conditions), cardiovascular findings (like LVEF and biomarkers), and the expected cardiotoxicity profile of planned cancer therapy. A higher score generally means a higher probability of treatment-related cardiac events, including declines in heart function, heart failure symptoms, arrhythmias, or ischemic complications.
How this calculator estimates risk
This page uses an educational point-based model inspired by HFA-ICOS principles. It is built to help users understand how multiple factors can stack together. The calculator assigns points for major risk domains:
- Demographics: older age contributes additional points.
- Cardiac function: lower baseline LVEF increases risk weight.
- Comorbid conditions: hypertension, diabetes, CKD, and pre-existing cardiovascular disease all add risk.
- Cardiac biomarkers: elevated troponin or BNP/NT-proBNP may indicate vulnerability.
- Prior exposures: previous anthracyclines and chest radiation can increase cumulative cardiac burden.
- Planned therapy profile: therapies with greater cardiotoxic potential receive higher points.
How to use the calculator
- Enter age and baseline LVEF.
- Select whether each risk factor is present.
- Choose the expected risk level of planned therapy.
- Click Calculate Score to view total points, category, and practical next steps.
If you are a patient, consider filling this out before an oncology or cardio-oncology visit and using the result as a conversation starter. If you are a clinician, this can serve as a quick triage aid before applying formal institutional protocols.
Interpreting score categories
Low risk (0-5)
Usually suggests routine baseline evaluation and standard follow-up intervals are appropriate, assuming no new symptoms emerge.
Moderate risk (6-9)
Indicates meaningful vulnerability. Patients may benefit from more frequent surveillance imaging and biomarker reassessment during treatment cycles.
High risk (10-14)
Strongly consider structured cardio-oncology follow-up, tighter blood pressure and metabolic optimization, and proactive symptom surveillance.
Very high risk (15+)
Often merits pre-treatment multidisciplinary review, individualized cardioprotective strategy, and early intervention planning if cardiac changes occur.
Why each factor matters
Baseline LVEF
LVEF provides a snapshot of how effectively the left ventricle pumps blood. Even mild pre-treatment reduction can lower reserve capacity during cardiotoxic therapy.
Prior cardiovascular disease
Existing heart failure, coronary disease, or structural heart disease signals less physiologic margin when treatment-related stress is added.
Kidney dysfunction and diabetes
Both are linked to endothelial dysfunction, inflammation, and higher long-term cardiovascular event rates, amplifying treatment risk.
Biomarkers
Elevated troponin or natriuretic peptides at baseline can indicate subclinical myocardial injury or hemodynamic stress, even before obvious imaging abnormalities appear.
Therapy class risk
Different regimens have different cardiotoxic signatures. For example, some therapies are associated with LV dysfunction, others with myocarditis, QT prolongation, hypertension, or thrombotic effects.
Example scenario
Consider a 68-year-old patient with LVEF 52%, hypertension, CKD, and prior anthracycline exposure, planned for high-risk therapy:
- Age 60-69: +1
- LVEF 50-54: +2
- Hypertension: +1
- CKD: +2
- Prior anthracycline: +2
- High-risk therapy: +4
Total = 12 points, which falls into the high-risk range in this educational model. This would support closer surveillance and early cardio-oncology involvement.
Best practices after calculating
- Confirm baseline echo quality and consider global longitudinal strain (if available).
- Review blood pressure, glucose, lipid, and renal status before treatment initiation.
- Plan interval biomarker checks for moderate-to-very-high risk patients.
- Educate patients on warning symptoms: dyspnea, edema, palpitations, chest discomfort, fatigue, sudden weight gain.
- Document a clear escalation pathway if early cardiotoxicity signs appear.
Limitations and clinical caution
No online calculator can capture every nuance of oncology and cardiology decision-making. Drug dose intensity, combination regimens, treatment duration, prior cumulative exposures, and patient frailty all influence real-world risk. This tool should be viewed as a structured prompt, not a final answer.
Always integrate risk scores with physical examination, ECG, echocardiography, lab data, and multidisciplinary discussion.
Frequently asked questions
Is this an official HFA-ICOS calculator?
No. It is an educational adaptation intended to mirror core cardio-oncology risk concepts in a practical way.
Can a low score rule out cardiotoxicity?
No. Even lower-risk patients can develop complications, so symptom awareness and guideline-concordant follow-up remain important.
Can this replace physician advice?
No. Use this output as a discussion tool with oncologists, cardiologists, and cardio-oncology specialists.
Bottom line
A structured HFA-ICOS-style assessment helps identify who might benefit from more intensive cardiovascular monitoring during cancer care. Use the calculator above to estimate baseline risk, then pair the result with personalized medical guidance for safe and effective treatment planning.